Gut Liver.  2013 Mar;7(2):206-212.

Metadherin Is a Prognostic Predictor of Hepatocellular Carcinoma after Curative Hepatectomy

Affiliations
  • 1Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ckpark@skku.edu

Abstract

BACKGROUND/AIMS
The prognosis after surgical resection of hepatocellular carcinoma (HCC) remains poor because of a high rate of recurrence. Thus, it is crucial to identify patients with a high risk of recurrence after curative hepatectomy and to develop more effective and targeted treatment strategies to improve disease outcomes. In this study, we investigated the roles of metadherin (MTDH) in the prognosis of HCC.
METHODS
We investigated MTDH expression using immunohistochemistry in tumor tissue microarrays of 288 primary HCC patients who underwent curative surgical resection.
RESULTS
High MTDH expression was observed in 138 of the 288 HCC cases (47.9%). High MTDH expression was associated with a younger age (p<0.001), higher Edmondson grade (p<0.001), microvascular invasion (p<0.001), higher American Joint Committee on Cancer T stage (p=0.001), and higher alpha-fetoprotein level (p=0.003). Multivariate analyses revealed that high MTDH expression (p=0.014), higher Barcelona-Clinic Liver Cancer (BCLC) stage (p<0.001), and Edmondson grade III (p=0.042) were independent predictors of shorter disease-free survival (DFS). Higher BCLC stage (p<0.001) and Edmondson grade III (p=0.047) were also independent predictors of shorter disease-specific survival.
CONCLUSIONS
High MTDH expression may be a prognostic predictor of shorter DFS in HCC patients after curative hepatectomy.

Keyword

Metadherin; Hepatocellular carcinoma; Survival

MeSH Terms

alpha-Fetoproteins
Carcinoma, Hepatocellular
Disease-Free Survival
Hepatectomy
Humans
Immunohistochemistry
Joints
Liver Neoplasms
Multivariate Analysis
Prognosis
Recurrence
alpha-Fetoproteins
Full Text Links
  • GNL
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr